-
Vemurafenib (INN), sold
under the
brand name
Zelboraf, is a
medication used for the
treatment of late-stage melanoma. It is an
inhibitor of the B-Raf enzyme...
-
monoclonal antibody approved to
treat rheumatoid arthritis (RA). 2011:
Zelboraf (vemurafenib): For the
treatment of
metastatic melanoma caused by BRAF...
-
vemurafenib (
Zelboraf)
alone or with both
vemurafenib and
atezolizumab (Tecentriq) to
treat melanoma.
Cobimetinib is a MEK inhibitor. Cotellic,
Zelboraf, and...
- (pexidartinib) (available only in the
United States)
Vanflyta (quizartinib)
Zelboraf (vemurafenib)
Cardiovascular Effient (prasugrel) (co-marketed with Eli...
-
approved by US FDA in Nov 2015 for use in
combination with
vemurafenib (
Zelboraf(R)), for
treatment of
advanced melanoma with a BRAF V600E or V600K mutation...
- (omalizumab), for asthma,
chronic idiopathic urticaria (CIU), and
nasal polyps.
Zelboraf (vemurafenib), for late-stage V600E BRAF mutation-positive melanoma. Zenapax...
- (RG7204 or PLX4032) was
licensed by the US Food and Drug
Administration as
Zelboraf for the
treatment of
metastatic melanoma in
August 2011
based on Phase...
-
carcinoma (NSCLC).
Temsirolimus (Torisel)
Everolimus (Afinitor)
Vemurafenib (
Zelboraf)
Trametinib (Mekinist)
Dabrafenib (Tafinlar)
Several are in development...
- U.S. Food and Drug
Administration (FDA)
approved the drug
vemurafenib (
Zelboraf) for
metastatic melanoma patients who test
positive for a
specific gene...
- Medicine. 368 (14): 1365–1366. doi:10.1056/NEJMc1302338. PMID 23550685. "
Zelboraf (vemurafenib) [package insert]" (PDF).
South San Francisco, CA: Genentech...
